To the best of our knowledge, the current study is the first to evaluate the effect of SGLT2 inhibitors on blood ketone body concentration, as assessed by β-OHB, in patients with CHF, and to analyse the relationship between changes in serum β-OHB levels and changes in vascular stiffness and BP. The gene discussed is SLC5A2; the disease is congestive heart failure.